Jaclyn Frances Hechtman

List of Publications by Citations

Source: https://exaly.com/author-pdf/8447373/jaclyn-frances-hechtman-publications-by-citations.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86 papers	6,222 citations	32 h-index	78 g-index
87 ext. papers	8,489 ext. citations	9.8 avg, IF	5.33 L-index

#	Paper	IF	Citations
86	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nature Medicine*, **2017**, 23, 703-713	50.5	1638
85	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. *Journal of Molecular Diagnostics*, **2015**, 17, 251-64	5.1	1066
84	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. *Cancer Cell*, **2018**, 33, 125-136.e3	24.3	338
83	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. *JAMA Oncology*, **2019**, 5, 471-478	13.4	257
82	Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. *American Journal of Surgical Pathology*, **2017**, 41, 1547-1551	6.7	231
81	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. *Science*, **2019**, 364, 485-491	33.3	228
80	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. *Clinical Cancer Research*, **2019**, 25, 2116-2126	12.9	219
79	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. *Modern Pathology*, **2020**, 33, 38-46	9.8	187
78	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. *Cancer Discovery*, **2018**, 8, 49-58	24.4	180
77	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. *Modern Pathology*, **2016**, 29, 1433-1442	9.8	108
76	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 821-831	21.7	104
75	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. *Clinical Cancer Research*, **2016**, 22, 2351-8	12.9	104
74	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. *Clinical Cancer Research*, **2019**, 25, 967-976	12.9	94
73	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. *Nature Medicine*, **2019**, 25, 1422-1427	50.5	87
72	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. *Nature Reviews Clinical Oncology*, **2020**, 17, 757-770	19.4	82
71	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. *Cancer Discovery*, **2019**, 9, 199-209	24.4	79
70	Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms. *Cancer Research*, **2019**, 79, 3163-3168	10.1	75

69	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. *Cancer Research*, **2019**, 79, 1047-1053	10.1	73
68	HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 691-7	5	69
67	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. *Journal of Molecular Diagnostics*, **2017**, 19, 244-254	5.1	66
66	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. *Clinical Cancer Research*, **2017**, 23, 4753-4760	12.9	47
65	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. *Clinical Cancer Research*, **2020**, 26, 1624-1632	12.9	47
64	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. *Clinical Cancer Research*, **2019**, 25, 6160-6169	12.9	45
63	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. *Modern Pathology*, **2017**, 30, 599-609	9.8	43
62	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. *Cancer Research*, **2017**, 77, 6513-6523	10.1	43
61	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. *Nature Communications*, **2017**, 8, 14674	17.4	38
60	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). *Modern Pathology*, **2015**, 28, 1123-9	9.8	37
59	Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. *Annals of Surgical Oncology*, **2015**, 22, 2633-9	3.1	34
58	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. *Molecular Cancer Research*, **2016**, 14, 296-301	6.6	34
57	Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature. *American Journal of Surgical Pathology*, **2011**, 35, 927-32	6.7	34
56	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. *Journal of Clinical Investigation*, **2018**, 128, 3819-3825	15.9	33
55	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. *Clinical Cancer Research*, **2021**, 27, 34-42	12.9	32
54	Clinical and genetic determinants of ovarian metastases from colorectal cancer. *Cancer*, **2017**, 123, 1134-1143	6.1	30
53	Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. *Genes Chromosomes and Cancer*, **2015**, 54, 177-84	5	23
52	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. *Modern Pathology*, **2020**, 33, 871-879	9.8	23

51	Germline mutations in children and adults with cancer. *Journal of Physical Education and Sports Management*, **2018**, 4,	2.8	20
50	Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. *Human Pathology*, **2013**, 44, 1400-5	3.7	19
49	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. *Molecular Cancer Research*, **2015**, 13, 1003-8	6.6	17
48	Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. *American Journal of Surgical Pathology*, **2012**, 36, 305-10	6.7	17
47	Lineage Reversion Drives WNT Independence in Intestinal Cancer. *Cancer Discovery*, **2020**, 10, 1590-1609	24.4	16
46	Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. *Oncotarget*, **2016**, 7, 50875-50882	3.3	15
45	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. *Cancer Discovery* , **2021**, 11, 126-141	24.4	15
44	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. *Familial Cancer*, **2017**, 16, 525-529	3	14
43	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. *Cancer Discovery*, **2019**, 9, 1182-1191	24.4	14
42	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. *Human Pathology*, **2016**, 53, 97-104	3.7	14
41	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. *Modern Pathology*, **2019**, 32, 110-121	9.8	14
40	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. *Hepatology*, **2021**, 74, 1429-1444	11.2	14
39	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. *Human Pathology*, **2017**, 62, 74-82	3.7	13
38	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. *Familial Cancer*, **2018**, 17, 225-228	3	13
37	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. *Annals of Surgical Oncology*, **2018**, 25, 2027-2033	3.1	12
36	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. *Molecular Cancer Research*, **2017**, 15, 708-713	6.6	11
35	Neurogenic polyps of the gastrointestinal tract: a clinicopathologic review with emphasis on differential diagnosis and syndromic associations. *Archives of Pathology and Laboratory Medicine*, **2015**, 139, 133-9	5	11
34	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. *Clinical Cancer Research*, **2021**, 27, 1316-1328	12.9	11

33	EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. *Pancreatology*, **2015**, 15, 302-4	3.8	10
32	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. *Nature Communications*, **2021**, 12, 3770	17.4	10
31	FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. *Clinical Colorectal Cancer*, **2019**, 18, e39-e52	3.8	9
30	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. *Clinical Cancer Research*, **2021**, 27, 1429-1437	12.9	9
29	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. *Journal of Molecular Diagnostics*, **2020**, 22, 368-375	5.1	8
28	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. *Modern Pathology*, **2019**, 32, 1551-1562	9.8	7
27	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. *Human Pathology*, **2019**, 83, 1-6	3.7	7
26	Ischemic bowel due to embolization from an isolated mobile thrombus of the ascending aorta: a case report and review of the literature. *Journal of Thrombosis and Thrombolysis*, **2011**, 32, 238-41	5.1	7
25	Efficacy of Combined VEGFR1-3, PDGFR and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. *Clinical Cancer Research*, **2019**, 25, 3811-3817	12.9	5
24	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. *Oncologist*, **2020**, 25, e68-e74	5.7	5
23	Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. *Cancer Medicine*, **2019**, 8, 6538-6548	4.8	5
22	Thymomas diagnosed during pregnancy: two cases in young women without paraneoplastic or autoimmune disease. *Annals of Diagnostic Pathology*, **2012**, 16, 392-6	2.2	5
21	Intramuscular corpora amylacea adjacent to ileal low-grade neuroendocrine tumours (typical carcinoids): a light microscopic, immunohistochemical and ultrastructural study. *Journal of Clinical Pathology*, **2013**, 66, 569-72	3.9	5
20	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. *Human Pathology*, **2020**, 106, 45-53	3.7	5
19	Subclinical focal Cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic Ductal Adenocarcinoma and Biliary tree intervention. *Cancer Imaging*, **2017**, 17, 21	5.6	4
18	Multiple endocrine neoplasia type 1 associated with a new mutation in the menin gene and a midgut neuroendocrine tumor. *Pancreas*, **2014**, 43, 145-6	2.6	4
17	Mycobacterial pseudotumor of the plantar fascia: how common is it?. *Clinical Imaging*, **2013**, 37, 802-5	2.7	4
16	Anti-glutamate receptor 2 as a new potential diagnostic probe for prostatic adenocarcinoma: a pilot immunohistochemical study. *Applied Immunohistochemistry and Molecular Morphology*, **2012**, 20, 344-9	1.9	4

15	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. *JAMA Network Open*, **2021**, 4, e2114753	10.4	4
14	Intraductal polypoid lipid-rich neuroendocrine tumor of the pancreas with entrapped ductules: case report and review of the literature. *Endocrine Pathology*, **2013**, 24, 30-5	4.2	3
13	Corpora amylacea in gastrointestinal leiomyomas: a clinical, light microscopic, ultrastructural and immunohistochemical study with comparison to hyaline globules. *Journal of Clinical Pathology*, **2013**, 66, 951-5	3.9	3
12	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 692-698	5	3
11	EGFR Amplification in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 1561-1569	9.7	3
10	Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	1
9	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. *Familial Cancer*, **2021**, 20, 201-213	3	1
8	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. *Clinical Cancer Research*, **2021**, 27, 3491-3498	12.9	1
7	The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy. *Cancer Cytopathology*, **2019**, 127, 428-431	3.9	0
6	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.. *JCO Precision Oncology*, **2022**, 6, e2100242	3.6	0
5	Current Management of Appendiceal Neoplasms. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2021**, 41, 1-15	7.1	0
4	Hepatic mass in a 73-year-old man. *Gastroenterology*, **2012**, 142, 434, 679	13.3	
3	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. *Blood*, **2017**, 130, 794-794	2.2	
2	Reply to Singh et al. *Modern Pathology*, **2021**, 34, 1033-1034	9.8	
1	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer.. *JCO Precision Oncology*, **2022**, 6, e2100365	3.6	